Outpatient Parenteral Antimicrobial Therapy in Neonates
Introduction to OPAT in Neonates
- The use of OPAT in neonates is limited due to clinical and technical factors, with only two case series reporting successful use at home with minimal complications, highlighting the need for more research on safety and efficacy, particularly for invasive infections like meningitis, as noted by pediatric infectious disease specialists 1
- Patient age is a crucial consideration for pediatric infectious disease specialists when deciding to use OPAT, with a lack of evidence on the safety and efficacy of OPAT using central catheters in neonates 1
Pain Management in Neonates
- For brief painful procedures like heel sticks and venipuncture, the American Academy of Pediatrics recommends a dose of 0.1 to 1 mL of 24% sucrose (or 0.2–0.5 mL/kg) 2 minutes prior, as well as the use of topical anesthetics such as EMLA and tetracaine gel, although caution is advised due to risks like methemoglobinemia and skin irritation, especially in preterm infants 2
Administration of OPAT and Management of Neonatal Opioid Withdrawal Syndrome (NOWS)
- The first dose of OPAT should be administered in a supervised healthcare setting to manage potential anaphylaxis, and for NOWS, first-line treatment should prioritize nonpharmacologic interventions, including environmental modifications and support for breastfeeding, as recommended by the American Academy of Pediatrics 3, 4, 1
- If nonpharmacologic measures fail, pharmacologic treatment may be necessary, with opioid therapy (e.g., methadone, morphine) or alternative treatments like clonidine, and weaning schedules should be carefully managed, such as decreasing methadone dose by 10% per day or increasing dosing interval gradually 3, 4
- Standardized assessment tools like the Modified Neonatal Abstinence Scoring System should be used for infants at risk for NOWS, with careful monitoring for late-onset withdrawal symptoms and follow-up visits every 2-4 weeks for the first 2-3 months, as recommended by the American Academy of Pediatrics 4
Monitoring and Follow-Up for Infants with NOWS
- Minimum observation periods for infants with NAS vary by substance, ranging from 3 days for short-acting opioids to 5-7 days for long-acting opioids, and developmental screening should be performed at each visit, with attention to motor milestones and nutritional assessment, as recommended by the American Academy of Pediatrics 4
- Early intervention services should be initiated at signs of developmental delay, with nutritional support if growth parameters are concerning, and caregiver support to address parenting challenges, and verification of HIV, hepatitis B, hepatitis C, and syphilis screening results from the prenatal or newborn period should be ensured, as recommended by the Centers for Disease Control and Prevention 4, 3, 5
- Most cases of non-opioid withdrawal resolve without long-term sequelae, and treatment of drug withdrawal may not alter the long-term outcome, emphasizing the importance of early outpatient follow-up after discharge and educating caregivers about potential late withdrawal signs, as noted by the American Academy of Pediatrics 4